Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

65
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
65
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

114
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
114
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

35
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
35
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

342
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
342
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

60
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
60
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

46
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
46

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

PCSK9 inhibition and cardiovascular outcomes by heart failure status: a pooled analysis of SPIRE-1 and SPIRE-2.

European journal of heart failure·2026
Same author

In Case You Missed It! European Society of Cardiology Heart Failure Association Congress 2026.

Journal of cardiac failure·2026
Same author

Mechanosensing by T cells promotes a tissue-resident memory transcriptional program.

Nature immunology·2026
Same author

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same author

Cystatin-C Versus Creatinine and Kidney Function in Heart Failure With Preserved Ejection Fraction: A SOGALDI-PEF Analysis.

The American journal of cardiology·2026
Same author

Correction: Description of new species of <i>Mycobacterium terrae</i> complex isolated from sewage at the São Paulo zoological park foundation in Brazil.

Frontiers in microbiology·2026

相关实验视频

Updated: Sep 16, 2025

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K

一个用于预测心脏病的混合框架,使用经典和量子启发的机器学习技术.

Ankur Kumar1, Sanjay Dhanka2, Abhinav Sharma2

  • 1School of Computing and Electrical Engineering (SCEE), Indian Institute of Technology (IIT) Mandi, Mandi, 175005, Himachal Pradesh, India.

Scientific reports
|July 11, 2025
PubMed
概括

这项研究引入了一种混合框架,将经典和量子启发的机器学习结合起来,以改善心脏病预测. 这种新的方法通过使用集成数据集和先进的优化技术来提高预测的准确性和稳定性.

关键词:
节律失常的分类类别是心律失常.功能选择 功能选择机器学习是机器学习.粒子群集优化优化 粒子群集优化皮尔森的相关系数

更多相关视频

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

726
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.5K

相关实验视频

Last Updated: Sep 16, 2025

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

726
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.5K

科学领域:

  • 心血管健康 心血管健康
  • 机器学习 机器学习
  • 计算科学 计算科学

背景情况:

  • 准确的心脏病预测对于及时干预和改善患者结果至关重要.
  • 现有的机器学习模型在预测准确性和稳定性方面面临挑战.
  • 整合多样化的数据集和先进的计算技术可能可以克服这些局限性.

研究的目的:

  • 提出和评估一种用于心脏病预测的新型混合框架.
  • 整合经典和量子启发的机器学习技术,以提高性能.
  • 将拟议框架与最先进的方法进行比较.

主要方法:

  • 开发了一个混合框架,结合了经典和量子启发的机器学习模型.
  • 来自多个心脏病数据集 (克利夫兰,匈牙利,瑞士,长,Statlog) 的数据被组合和预处理.
  • 支持矢量机 (SVM) 分类器使用遗传算法 (CGA),粒子群优化 (CPSO),量子遗传算法 (QGA) 和量子粒子群优化 (QPSO) 进行了训练和优化.
  • 使用十倍交叉验证来评估使用各种指标的性能,包括准确性,F1得分,精度,灵敏度,特异性和诊断几率比率 (DOR).

主要成果:

  • 与现有方法相比,混合框架证明了心脏病预测准确度和稳定性的提高.
  • 经典模型和量子模型都表现出了竞争力的表现,混合方法提供了增强的功能.
  • 特性选择和严格的交叉验证确保了可靠的模型评估.

结论:

  • 拟议的混合框架整合了经典和量子启发的机器学习,显示了促进心脏病预测的巨大潜力.
  • 这种新的方法提供了一种强大而准确的方法来识别心脏病风险较高的人.
  • 进一步的研究可以探索这种混合框架在临床环境中的更广泛应用.